Orexigen Therapeutics (Nasdaq: OREX) lost 23 cents per share in the first quarter of 2014, wider than the year-ago loss of 21 cents and deeper than Wall Street expectations of a 20-cent loss.
3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037
All contents herein copyright San Diego Source | The Daily Transcript ® 1994-2014